CBChristophe Van Berckelaer

Christophe Van Berckelaer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christophe Van Berckelaer has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol

    by Tom Quisenaerts, Ilse Van Der Auwera, Philip Poortmans, Dries Reynders, Loïc Van Dieren, Filip Thiessen, Zainab Amajoud, Thierry Tondu, Kevin Punie, Wiebren Tjalma, et al.

    Currently there is a wide practice variation in breast reconstruction surgery after mastectomy for breast cancer patients, especially when radiation therapy (RT) is involved. While it is clear from the scientific literature that immediate implant-based reconstruction has an increased complication rate when postmastectomy Radiation therapy (PMRT) is administered, the jury is out on autologous immediate breast reconstructions (IBR). Nevertheless, some clinicians avoid autologous IBR due to aesthetic outcomes being negatively influenced by PMRT. Others only place tissue expanders, or avoid IBR altogether, when PMRT is indicated. This leads to prolonged periods of time where the patient must live without a new breast, inferior aesthetic outcomes, or an increase in complications. This phase 3 clinical trial, building on the PRADA pilot study, will investigate the efficacy and safety of preoperative RT combined with IBR. In this open-label, multicentre, phase 3, randomised controlled trial, 180 female participants with a new diagnosis of breast cancer will be enrolled. Participants will be randomised into two groups. The first group (control) will receive the standard of care treatment (SoC) consisting of mastectomy followed by PMRT; in this group the breast reconstruction can be either delayed or immediate. The second group (experimental) consists of preoperative RT followed by mastectomy and IBR. After treatment conclusion, follow-up will take place at 3 months, 1, 2, 5, and 10 years after the last study treatment. The primary outcome is the patient reported outcome measure of satisfaction with breasts (BREAST-Q score) at 1 year of follow-up. Secondary outcomes include cosmetic assessment, quality of life, adverse events, treatment duration, and histopathology response rates, tertiary endpoints include oncological survival outcomes according to DATECAN definitions. The trial sponsor is ZAS vzw, and is funded by ‘Kom op tegen kanker’. Preoperative RT has been implemented in multiple other types of cancer and could offer an opportunity to improve aesthetic and quality of life outcomes in breast cancer patients. Based on the PRADA pilot study and similar research, no increase in adverse events or worse oncological outcomes is expected from this change in treatment sequence. ClinicalTrials.gov: NCT06739655; First registration: 17-DEC-2024. Local ZAS Augustinus trial-ID: CTO23023GZA; First registration: 22-APR-2024.

  • Open Access

    XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant

    by Christophe Van Berckelaer, Steven Van Laere, Seayoung Lee, Michael A Morse, Joseph Geradts, Luc Dirix, Mark Kockx, François Bertucci, Peter Van Dam, Gayathri R Devi


  • Open Access

    A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer

    by C. Van Berckelaer, M. Van Geyt, S. Linders, C. Rypens, X.B. Trinh, W.A.A. Tjalma, S. Van Laere, C. Colpaert, L. Dirix, P.A. van Dam


  • Open Access

    The immunologic aspects in hormone receptor positive breast cancer

    by Gizem Oner, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Christophe Van Berckelaer, Glenn Broeckx, Karen Zwaenepoel, Maria Tholhuijsen, Yannick Verhoeven, Zwi Berneman, et al.


  • Triple‐negative breast cancer—Role of immunology: A systemic review

    by Gizem Oner, Sevilay Altintas, Zafer Canturk, Wiebren Tjalma, Yannick Verhoeven, Christophe Van Berckelaer, Zwi Berneman, Marc Peeters, Patrick Pauwels, Peter A. Dam

    Recently, the complex role of immune therapy has been the target of increased attention in breast cancer, particularly in triple‐negative breast cancer (TNBC). Although TNBC is sensitive to chemotherapy, the recurrence and mortality rates are worse compared with the other breast cancer types. In addition, TNBC still lacks targeted treatment options. With the improved understanding of the immune system in TNBC, it is expected that new predictive and prognostic markers will be identified, and innovative treatment modalities will be developed. The aim of this review was to provide an overview of the effector cells in the TNBC's microenvironment and to highlight a novel approach to treat this kind of cancer. A computer‐based literature research was carried out using PubMed, American Society of Clinical Oncology Annual Meeting (ASCO) and San Antonio Breast Cancer Symposium (SABCS). To date, studies have shown that tumor‐infiltrating lymphocytes (TILs) and tumor‐associated macrophages (TAMs) play a very important role in the TNBC's microenvironment. Tumor‐infiltrating lymphocytes can even be considered as biomarkers to predict chemotherapy response in TNBC. Furthermore, TNBC was shown to have immune active subtypes, and therefore, the use of immunotherapy may be an attractive treatment approach. In this respect, several randomized studies have been designed or are currently ongoing to explore the combination of chemotherapy with immunotherapy in TNBC. Combination of chemo‐ and immunotherapy is likely to be beneficial in a subgroup of patients with TNBC.


  • Open Access

    Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

    by C. Van Berckelaer, C. Rypens, P. van Dam, L. Pouillon, M. Parizel, K. A. Schats, M. Kockx, W. A. A. Tjalma, P. Vermeulen, S. van Laere, et al.

    Inflammatory breast cancer (IBC) is a rare and rapidly progressive form of invasive breast cancer. The aim of this study was to explore the clinical evolution, stromal tumour-infiltrating lymphocytes (sTIL) infiltration and programmed death-ligand 1 (PD-L1) expression in a large IBC cohort. Data were collected prospectively from patients with IBC as part of an international collaborative effort since 1996. In total, 143 patients with IBC starting treatment between June 1996 and December 2016 were included. Clinicopathological variables were collected, and sTIL were scored by two pathologists on standard H&E stained sections. PD-L1 expression was assessed using a validated PD-L1 (SP142) assay. A validation cohort of 64 patients with IBC was used to test our findings. Survival outcomes of IBC remained poor with a 5-year overall survival (OS) of 45.6%. OS was significantly better in patients with primary non-metastatic disease who received taxane-containing (neo)adjuvant therapy (P = 0.01), had a hormone receptor-positive tumour (P = 0.001) and had lower cN stage at diagnosis (P = 0.001). PD-L1 positivity on immune cells (42.9%) was higher in IBC than in non-IBC in both our patient samples and the validation cohort. Furthermore, PD-L1 expression predicted pCR (P = 0.002) and correlated with sTIL infiltration (P < 0.001). sTIL infiltration of more than 10% of the stroma was a significant predictor of improved OS (HR 0.47, 95% CI 0.27–0.81, P = 0.006) in a multivariate model. IBC is characterised by poor survival and high PD-L1 immunoreactivity on sTIL. This suggests a role for PD1/PD-L1 inhibitors in the treatment of IBC. Furthermore, we showed that PD-L1 expression predicts response to neo-adjuvant therapy and that sTIL have prognostic significance in IBC.